Lipocine (LPCN) Current Assets (2011 - 2025)
Lipocine's (LPCN) quarterly Current Assets came in at $16.9 million in Q4 2025, down 24.39% YoY from $22.3 million in Q4 2024, and up 5.95% on a QoQ basis from $15.9 million in Q3 2025.
Lipocine (LPCN) Current Assets (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Current Assets data on file, last reported at $16.9 million in Q4 2025.
- Quarterly Current Assets fell 24.39% year-over-year to $16.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.9 million (down 24.39% YoY) and the FY2025 annual result came in at $16.9 million, down 24.39% from the prior year.
- Current Assets rose to $16.9 million in Q4 2025, from $15.9 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $47.2 million in Q2 2021 to a low of $15.9 million in Q3 2025.
- A 5-year average of $30.0 million and a median of $26.2 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets surged 119.14% — and 2023, when it slumped 33.03%.
- Tracing LPCN's Current Assets over 5 years: stood at $46.4 million in 2021, then retreated by 26.4% to $34.1 million in 2022, then slumped by 33.03% to $22.9 million in 2023, then fell by 2.36% to $22.3 million in 2024, then decreased by 24.39% to $16.9 million in 2025.
- The last three Current Assets figures came in at $16.9 million (Q4 2025), $15.9 million (Q3 2025), and $18.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | 16.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.88 Mn |
| Sep 30, 2025 | 15.93 Mn |
| Jun 30, 2025 | 18.42 Mn |
| Mar 31, 2025 | 20.33 Mn |
| Dec 31, 2024 | 22.32 Mn |
| Sep 30, 2024 | 20.50 Mn |
| Jun 30, 2024 | 22.91 Mn |
| Mar 31, 2024 | 25.32 Mn |
| Dec 31, 2023 | 22.86 Mn |
| Sep 30, 2023 | 24.61 Mn |
| Jun 30, 2023 | 27.08 Mn |
| Mar 31, 2023 | 30.61 Mn |
| Dec 31, 2022 | 34.14 Mn |
| Sep 30, 2022 | 36.11 Mn |
| Jun 30, 2022 | 38.08 Mn |
| Mar 31, 2022 | 43.50 Mn |
| Dec 31, 2021 | 46.38 Mn |
| Sep 30, 2021 | 40.37 Mn |
| Jun 30, 2021 | 47.16 Mn |
| Mar 31, 2021 | 45.94 Mn |